CIA
OCUL icon

Capital Impact Advisors’s Ocular Therapeutix OCUL Stock Holding History

Capital Impact Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-13,211
Closed -$186K – 272
2015
Q3 		$186K Hold
13,211
– – 0.09% 240
2015
Q2 		$278K Hold
13,211
– – 0.13% 239
2015
Q1 		$555K Buy
+13,211
New +$434K 0.25% 183

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Impact Advisors's OCUL Position: Q4 2015 in Review

Capital Impact Advisors sold out of Ocular Therapeutix (OCUL) in Q4 2015, closing a stake of 13,211 shares — an estimated $186K sold.

Capital Impact Advisors first reported a position in OCUL in Q1 2015 and held it in 3 quarters. The position peaked at $555K in Q1 2015. 71 funds tracked by Wall St. Rank hold OCUL as of Q4 2015.

  • Capital Impact Advisors reported no remaining Ocular Therapeutix position as of Q4 2015 after selling out during the quarter.
  • Capital Impact Advisors sold 13,211 Ocular Therapeutix shares in Q4 2015, an estimated $186K.
  • Capital Impact Advisors first reported a position in Ocular Therapeutix in Q1 2015 and held it in 3 quarters.
  • Capital Impact Advisors's Ocular Therapeutix position peaked at $555K in Q1 2015.
  • 71 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2015.

Based on Capital Impact Advisors's 13F filing for Q4 2015, filed 11 Jan 2016.